title: [Clinical significant of semiquantificating DNA topoisomerase- I mRNA in colorectal cancer].
abstract: OBJECTIVE
  To examine the clinical significance of determining the expression levels of DNA topoisomerase- I (topo-I) mRNA of colorectal cancer.
  
  
  METHODS
  The relative expression levels of topo-I mRNA in primary colorectal cancer and adjacent normal mucosa were semiquantificated by the RT-PCR method. The relative expression of thymidylate synthase (TS) mRNA of the primary lesions was also examined.
  
  
  RESULTS
  The topo- I mRNA expression was higher in the tumorous tissue than in the normal mucosa (n=22, p<0.01). The topo- I mRNA expression did not significantly correlate with 9 clinicopathological variables examined (n=22). In patients who received irinotecan hydrochloride (CPT-11) following the failure of 5-fluorouracil-based treatment, the topoI mRNA expression did not differ nor correlate with the response to CPT-11 (PR, n=14; SD, n=11; PR; n=24) (p=0.91). In these patients, there was no relationship between the topo I mRNA expression and the TS mRNA expression (p=0.22, r=0.18). In addition, the efficacy of CPT-11 did not correlate with combinations subdivided according to the expression levels of topo- I mRNA and TS mRNA.
  
  
  CONCLUSIONS
  Determination of topo- I mRNA levels of primary colorectal cancer may not be useful for predicting the efficacy of CPT-11 treatment alone or in combination with TS mRNA levels.
authors.affiliation: Dept. Digestive Tract and General Surgery.
authors.forename: Hideyuki
authors.initials: H
authors.lastname: Ishida
authors.forename: Kazuo
authors.initials: K
authors.lastname: Shirakawa
authors.forename: Tomonori
authors.initials: T
authors.lastname: Ohsawa
authors.forename: Yoichi
authors.initials: Y
authors.lastname: Hayashi
authors.forename: Norimichi
authors.initials: N
authors.lastname: Okada
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Nakada
authors.forename: Masaru
authors.initials: M
authors.lastname: Yokoyama
mesh_terms: D000368:Aged; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use; D002166:Camptothecin / Q000031:analogs & derivatives / Q000627:therapeutic use; D015179:Colorectal Neoplasms / Q000188:drug therapy / Q000201:enzymology* / Q000473:pathology; D004264:DNA Topoisomerases, Type I / Q000235:genetics / Q000378:metabolism*; D005260:Female; D006801:Humans; D000077146:Irinotecan; D008297:Male; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D012333:RNA, Messenger / Q000378:metabolism; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013940:Thymidylate Synthase / Q000378:metabolism
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D012333:RNA, Messenger; D000077146:Irinotecan; D013940:Thymidylate Synthase; D004264:DNA Topoisomerases, Type I; D002166:Camptothecin